Allscripts announces Allscripts eRecruit, new initiative to improve population health
Allscripts eRecruit™ service empowers physicians to learn about latest clinical trials for their patients, and clinical research organizations to introduce new treatments to market quickly
CHICAGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ:MDRX) announced today its latest initiative to improve population health, Allscripts eRecruit™ services. This multi-faceted initiative will offer services and technology to support physicians with referring patients to clinical trials, and life sciences and clinical research organizations to reduce clinical studies’ time and cost. This, in turn will help bring new treatments to the market more quickly.
Allscripts eRecruit, the initial offering of Allscripts Clinical Trials Solutions, enables more effective clinical trials recruitment from Allscripts broad provider network and large patient population. eRecruit focuses specifically on helping CROs determine if a trial is feasible within the Allscripts population, and facilitating enrollment of the qualified patients the trial requires. The solution also assists with recruiting patients to participate in these studies through engagements with their providers. This offering provides an avenue for clinical research and life sciences organizations to better recruit for treatment research, providers to find relevant clinical trials for their patients, and patients to engage in innovative care.
Allscripts is partnering with ePatientFinder® to further eRecruit’s patient matching, outreach and recruiting capabilities. The ePatientFinder Clinical Trial Exchange™ platform helps physicians learn about the latest clinical trial options for their patients to provide high-quality referrals.
“We very excited to partner with Allscripts to provide their large provider base access to the Clinical Trial Exchange, the only platform of its kind that leverages the trusted physician-patient relationship and EHR data to match patients with trials for advanced care,” said Tom Dorsett, CEO of ePatientFinder. "We applaud Allscripts for bringing eRecruit to both the provider and life-science communities.”
“Allscripts eRecruit is the latest way that Allscripts is connecting communities to foster population health,” said Jay Bhattacharyya, Allscripts Vice President and General Manager, Payer/Life Sciences. “Providers want to keep up with the latest research that helps improve patient outcomes. eRecruit helps providers better connect their patients to these clinical trials. We are excited to continue to expand our offerings in this space and lead the way in population health innovation.”
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2016 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact: Investors: Seth Frank 312-506-1213 seth.frank@allscripts.com Media: Concetta DiFranco 312-447-2466 concetta.difranco@allscripts.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.